Last update 29 Oct 2026
IQVIA RDS (Shanghai) Co. Ltd.

IQVIA RDS (Shanghai) Co. Ltd.

Subsidiary Company|2013|Shanghai Shi, China|
www.iqvia.com

Overview

Tags

Nervous System Diseases
Digestive System Disorders
Other Diseases
Small molecule drug
ASO

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Hemic and Lymphatic Diseases1
Neoplasms1
Immune System Diseases1
Infectious Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug3
ASO1
Top 5 TargetCount
IL-6 x TGF-β x TNF-α1
MIR124 x RT1
Nav1.1(Sodium channel protein type I alpha subunit)1
Bcr-Abl x PDGFRs1

Related

4
Drugs associated with IQVIA RDS (Shanghai) Co. Ltd.
Radotinib Dihydrochloride
Target
Bcr-Abl x PDGFRs
Mechanism
Bcr-Abl inhibitors [+1]
Active Org.
IlYang Pharmaceutical Co., Ltd.IlYang Pharmaceutical Co., Ltd. [+1]
Originator Org.
IlYang Pharmaceutical Co., Ltd.IlYang Pharmaceutical Co., Ltd.
Active Indication
Philadelphia chromosome positive chronic myelogenous leukemia [+3]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
South Korea
First Approval Date05 Jan 2012
Deupirfenidone
Target
IL-6 x TGF-β x TNF-α
Mechanism
IL-6 inhibitors [+2]
Active Org.
PureTech Health PlcPureTech Health Plc [+3]
Originator Org.
Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd.
Active Indication
Idiopathic Pulmonary Fibrosis
Inactive Indication
Lymphedema [+1]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
Zorevunersen sodium
Target
Nav1.1
Mechanism
Nav1.1 blockers
Active Org.
IQVIA RDS (Shanghai) Co. Ltd.IQVIA RDS (Shanghai) Co. Ltd. [+2]
Originator Org.
Stoke Therapeutics, Inc.Stoke Therapeutics, Inc.
Active Indication
Epilepsies, Myoclonic
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
4
Clinical Trials associated with IQVIA RDS (Shanghai) Co. Ltd.
NCT04840849
/ CompletedPhase 1
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults
CTR20200160
/ TerminatedPhase 3
一项旨在检查DAS181治疗免疫功能低下受试者下呼吸道副流感病毒感染的有效性和安全性的III期、随机化、安慰剂对照研究
[Translation] A Phase III, randomized, placebo-controlled study to examine the efficacy and safety of DAS181 for the treatment of lower respiratory tract parainfluenza virus infections in immunocompromised subjects
CTR20200507
/ CompletedPhase 4
一项在中国常规医疗实践中进行的关于诺西那生钠注射液的多中心，非干预性的上市后监测研究
[Translation] A multicenter, non-interventional post-marketing surveillance study of SPINRAZA in routine medical practice in China
100 Clinical Results associated with IQVIA RDS (Shanghai) Co. Ltd.
Login to view more data
0 Patents (Medical) associated with IQVIA RDS (Shanghai) Co. Ltd.
Login to view more data
100 Deals associated with IQVIA RDS (Shanghai) Co. Ltd.
Login to view more data
100 Translational Medicine associated with IQVIA RDS (Shanghai) Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
2
Phase 3
NDA/BLA
1
2
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free